Current Therapies for Lupus Nephritis in an Ethnically Heterogeneous Cohort
Authors:
- H. Michael BelmontHBH. Michael Belmont
- Seema MalaniSMSeema Malani
- Melissa LatorreMLMelissa Latorre
- Lauri BentonLBLauri Benton
- Joseph WeisstuchJWJoseph Weisstuch
- Laura BarisoniLBLaura Barisoni
- Chung-E TsengCTChung-E Tseng
- Peter M. IzmirlyPIPeter M. Izmirly
- Jill P. BuyonJBJill P. Buyon
- Anca D. AskanaseAAAnca D. Askanase
- 9 February 2009
- journal article
- research article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 36 (2) , 298-305
Abstract
Objective.: To evaluate responses to mycophenolate mofetil (MMF) and intravenous cyclophosphamide (CYC) in lupus nephritis in a multiethnic population.Methods.: This was a retrospective study of all patients with systemic lupus erythematosus (SLE) that underwent kidney biopsy at New York University Medical Center. Patients with followup of at least 6 months were included. Clinical response was defined as complete (return to ± 10% of normal) or partial (improvement of 50% in abnormal renal measurements).Results.: Ninty-nine patients were included in the study: 86% females, 86% non-Caucasian, age 34.2 ± 1.1 years, 62% with proliferative nephritis (PN; ISN/RPS-III and IV), and 32% with membranous nephritis (MN; ISN/RPS-V). Of the 70 patients with PN, 37 were treated with CYC and 33 with MMF. The baseline characteristics of the 2 treatment groups were different in the incidence of ISN/RPS-IV, values of serum creatinine and serum albumin, and type of insurance (p < 0.05). The response rate was greater in the MMF than in the CYC group (70% vs 41%). Responses to MMF were different in Asians (11/11), Caucasians (4/5), African Americans (3/5), and Hispanics (5/11). Responses to CYC had a similar distribution (Asians 6/10, Caucasians 4/5, African Americans 4/9, Hispanics 1/11). In the MN group (N = 23) responses were similar to the PN group (73% MMF and 38% CYC). After adjusting for race, serum creatinine, serum albumin, type of insurance, and class of nephritis, in a logistic regression model, response to MMF was superior to CYC: OR 6.2 (95% CI 1.9–20.2). Hispanics had worse outcome than Caucasians (OR 0.17). Longterm followup suggested no difference in maintenance with MMF or CYC.Conclusion.: After controlling for the fact that less severe nephritis is preferentially treated with MMF, we found overall that response to MMF was superior to CYC. In this US population, ethnicity was observed to have an influence on response.Keywords
This publication has 15 references indexed in Scilit:
- Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trialsNephrology Dialysis Transplantation, 2007
- Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritisArthritis Research & Therapy, 2006
- Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus NephritisNew England Journal of Medicine, 2005
- Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXI. Disease activity, damage accrual, and vascular events in pre‐ and postmenopausal womenArthritis & Rheumatism, 2005
- Long-Term Study of Mycophenolate Mofetil as Continuous Induction and Maintenance Treatment for Diffuse Proliferative Lupus NephritisJournal of the American Society of Nephrology, 2005
- Sequential Therapies for Proliferative Lupus NephritisNew England Journal of Medicine, 2004
- Efficacy of Mycophenolate Mofetil in Patients with Diffuse Proliferative Lupus NephritisNew England Journal of Medicine, 2000
- Mycophenolate mofetil and its mechanisms of actionImmunopharmacology, 2000
- Long‐term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone onlyArthritis & Rheumatism, 1991
- Therapy of Lupus NephritisNew England Journal of Medicine, 1986